

**October 31, 2011**

# **Presentation for Investors**

**1H FY2011 (April 1 – September 30, 2011)**  
**Financial Results**

**Translation of presentation material for the investor meeting held in Tokyo on October 31, 2011**



# New Segmentation

◆ Reflecting organizational changes implemented in June 2011

◆ Major organizational change


Creation of Performance Materials Division to consolidate Electronic Materials Division and Inorganic Materials Division aiming to strengthen performance materials business which is identified as our major growth engine

◆ Major changes in segmentation

Creation of Performance Materials → Electronic Materials + Inorganic Materials

Change in Chemicals → Inorganic Materials shifted to Performance Materials  
Creation of Fine Chemicals subsegment, abolishment of Organic Materials subsegment  
Environmental Chemicals (HI-LITE) shifted from basic Chemicals to Fine Chemicals

Former Segmentation		
Segment	Main Products	
Chem	Organic Materials	TEPIC Melamine cyanurate Custom Chemicals
	Inorganic Materials	SNOWTEX Organo silica sol Alumina sol SUNCOLLOID CELNAX
	Basic Chemicals	Melamine Urea, AdBlue HI-LITE Ammonia, Sulfuric acid, Nitric acid High purity chemicals
Electronic Materials	SUNEVER, BARC NHC Multi layer process materials Micro lens	
Agro Chem	Agro	Herbicides Insecticides Fungicide
Pharma	LIVALO	
Trading	Nissei Corporation	
Others	Nissan Butsuryu, Nissan Green & Landscape, Nissan Engineering, Fertilizer	
Adjustment	R&D expenses of Advanced Materials & Planning Dept. included	



New Segmentation		
Segment	Main Products	
Chem	Fine Chemicals	TEPIC Melamine cyanurate HI-LITE Custom Chemicals
	Basic Chemicals	Melamine Urea, AdBlue Ammonia, Sulfuric acid, Nitric acid High purity chemicals
Performance Materials	SUNEVER, BARC, NHC, Multi layer process materials Micro lens SNOWTEX, Organo silica sol Alumina sol, SUNCOLLOID CELNAX	
Agro Chem	Agro	Herbicides Insecticides Fungicide
Pharma	LIVALO	
Trading	Nissei Corporation	
Others	Nissan Butsuryu, Nissan Green & Landscape, Nissan Engineering, Fertilizer	
Adjustment	R&D expenses of Advanced Materials & Planning Dept. included	

# Diversified Product Portfolio

◆ Consisting of products holding strong position in market

( ¥ billion)

NCI's Position

Chem	1H FY2011 Sales			
Fine Chemicals	5.9 (8.5%)	TEPIC	Epoxy compound for painting, LED sealant, solder resist	Largest (World)
Basic Chemicals	12.7 (18.2%)	High purity sulfuric acid	Agents for cleaning semiconductors	Largest (Japan)
		AdBlue	Urea to reduce NOx for diesel trucks	Among top 3 (Japan)
Performance Materials	17.0 (24.4%)	SUNEVER	LCD alignment coating	Major (Asia)
		BARC	Anti-reflective coating for semiconductor	Largest (Asia)
Agro	12.5 (17.9%)	SNOWTEX	Silica sol for polishing silicon wafer catalyst, non-chrome electrical steel sheet, etc.	Largest (Japan)
Pharma	5.2 (7.4%)	ROUNDUP	Non-selective herbicide	Largest (Japan)
		SIRIUS	Paddy rice herbicide	No.3 (Japan)
Trading	22.5 (32.2%)			
Others	9.3 (13.3%)	LIVALO	Anti-cholesterol drug	No.3 (Japan)

# 1H FY2011 PL

(¥billion)

	1H FY2010	1H FY2011	Change	1H FY2011 Outlook as of May 2011
Sales	72.1	69.8	-2.3	70.0
Operating Profit	8.3	6.6	-1.7	8.0
Non-Operating Income/Expenses	-0.5	-0.1	0.4	0.2
Ordinary Income	7.8	6.5	-1.3	8.2
Extraordinary Profit/Loss	-	-	-	-
Net Income	5.6	4.4	-1.2	5.5
EBITDA (1)	13.2	11.5	-1.7	13.0
EPS (¥)	32.81	25.88	-6.93	32.33
Dividend (¥/share)	¥12	¥12	¥0	¥12
Total amount of Dividend	2.1	2.1	0.0	2.1
OP Margin (%)	11.6%	9.4%	-2.2%	11.4%
FX Rate (¥/\$)	89	80		83
Naphtha (¥/KL)	46,900	55,000		59,000
Comprehensive Income	4.3	4.0		

(1) EBITDA = Operating Profit + Depreciation

# 1H FY2011 Review

## <vs. FY2010>

(Sales) ◆Down ¥2.3 billion (-3.2%) (+) Chemicals, Agrochemicals, Pharmaceuticals, Trading  
(-) Performance Materials

(OP) ◆Down ¥1.7 billion (-20.5%) (+) Chemicals, Pharmaceuticals  
(±) Agrochemicals, Trading  
(-) Performance Materials

(Non-Operating Income and Expenses) ◆Up ¥0.4 billion Equity in earnings of affiliates +0.4, Foreign exchange losses +0.3, Profit on sales of securities -0.3

(Ordinary Income) ◆Down ¥1.3 billion (-16.7%)

(Net Income) ◆Down ¥1.2 billion (-21.4%)

## <vs. 1H FY2011 Outlook as of May 2011>

(Sales) ◆Down ¥0.2 billion (+) Pharmaceuticals, Trading  
(±) Chemicals  
(-) Performance Materials, Agrochemicals

(OP) ◆Down ¥1.4 billion (+) Pharmaceuticals, Trading  
(-) Chemicals, Performance Materials, Agrochemicals

(Non-Operating Income and Expenses) ◆Down ¥0.3 billion Foreign exchange losses -0.3

(Ordinary Income) ◆Down ¥1.7 billion

(Net Income) ◆Down ¥1.1 billion

<Dividend > ◆¥12 Same as 1H FY2011 Outlook as of May 2011

# 1H FY2011

## Non-Operating Income/Expenses, Extraordinary Profit/Loss, Comprehensive Income

(¥billion)

	1H FY2010	1H FY2011	Change
<b>Non-Operating Income</b>	<b>1.28</b>	<b>0.91</b>	<b>-0.37</b>
Interest income	0.03	0.01	-0.02
Dividend income	0.31	0.32	0.01
Others	0.91	0.58	-0.33
<b>Non-Operating Expenses</b>	<b>1.78</b>	<b>0.96</b>	<b>-0.82</b>
Interest expense	0.28	0.23	-0.05
Loss on disposal of fixed assets	0.16	0.12	-0.04
Others	1.34	0.61	-0.73
<b>Extraordinary Profit</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Extraordinary Loss</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Comprehensive Income</b>	<b>4.31</b>	<b>4.00</b>	<b>-0.31</b>
Net income	5.60	4.40	-1.20
Minority interests	0.02	0.04	0.02
Unrealized gains or losses on investment securities	-0.94	0.05	0.99
Foreign currency translation adjustments	-0.37	-0.49	-0.12

# 1H FY2011 Cash Flow

(¥billion)

	1H FY2010	1H FY2011
<b>CF from operating activities</b>	<b>21.8</b>	<b>20.4</b>
Profit before income tax	7.8	6.5
Depreciation & Amortization	4.9	4.9
Tax	-3.7	-3.1
Working capital, others	12.8	12.1
<b>CF from investing activities</b>	<b>-2.9</b>	<b>-6.3</b>
Purchase of investments in securities	0.6	-0.9
Purchase of PPE	-2.7	-4.9
Others	-0.8	-0.5
<b>CF from financing activities</b>	<b>-18.3</b>	<b>-9.6</b>
Dividends paid	-2.4	-2.0
Borrowings	-13.0	-7.5
Purchase of treasury shares	-2.8	0.0
Others	-0.1	-0.1
Effect of FX rate changes on cash & cash equivalents	-0.3	-0.4
<b>Change in cash &amp; cash equivalents</b>	<b>0.3</b>	<b>4.1</b>
<b>Cash &amp; cash equivalents at end of period</b>	<b>15.1</b>	<b>25.2</b>



# 1H FY2011 Balance Sheets

(¥billion)

	2010/9	2011/3	2011/9	Change
<b>Current assets</b>	<b>91.8</b>	<b>110.5</b>	<b>100.1</b>	<b>-10.4</b>
Cash	15.1	21.1	25.2	4.1
Accounts receivable	40.7	55.2	40.2	-15.0
Inventories	30.3	28.4	29.7	1.3
Others	5.7	5.8	5.0	-0.8
<b>Fixed assets</b>	<b>72.8</b>	<b>72.9</b>	<b>72.7</b>	<b>-0.2</b>
Total PPE (1)	46.2	46.4	45.8	-0.6
Intangible assets	3.7	3.4	3.1	-0.3
Investment securities	19.3	20.3	21.4	1.1
Others	3.6	2.8	2.4	-0.4
<b>Total assets</b>	<b>164.6</b>	<b>183.4</b>	<b>172.8</b>	<b>-10.6</b>

(1) Increase in PPE	3.9
Depreciation	4.4
Retirement	0.1
<b>Change</b>	<b>-0.6</b>

	2010/9	2011/3	2011/9	Change
<b>Liabilities</b>	<b>57.9</b>	<b>71.0</b>	<b>58.6</b>	<b>-12.4</b>
Accounts payable	12.6	15.4	12.7	-2.7
Borrowings	29.1	39.9	32.4	-7.5
Others	16.2	15.7	13.5	-2.2
<b>Net assets</b>	<b>106.7</b>	<b>112.4</b>	<b>114.2</b>	<b>1.8</b>
<b>Shareholders' equity</b>	<b>105.8</b>	<b>111.1</b>	<b>113.5</b>	<b>2.4</b>
Unrealized gains or losses on investment securities	0.9	1.4	1.5	0.1
Foreign currency translation adjustments	-1.1	-1.2	-1.7	-0.5
Minority interests	1.0	1.1	0.9	-0.2
<b>Total liabilities &amp; Net assets</b>	<b>164.6</b>	<b>183.4</b>	<b>172.8</b>	<b>-10.6</b>

(Equity Ratio) 64.2% 60.7% 65.6%

Change in shareholders' equity 2.4 = Net Income 4.4 - Dividend 2.0

(Blank)

# 1H FY2011 Review by Segment (1)

(¥billion)

		Sales				OP			
		1H FY2010	1H FY2011	Change	1H FY2011 Outlook as of May 2011	1H FY2010	1H FY2011	Change	1H FY2011 Outlook as of May 2011
Chem		18.5	18.6	0.1	18.6	0.6	0.8	0.2	1.1
	Fine Chemicals	6.1	5.9	-0.2	5.9	-	-	-	-
	Basic Chemicals	12.4	12.7	0.3	12.7	-	-	-	-
Performance Materials		19.7	17.0	-2.7	18.9	4.9	2.6	-2.3	3.6
Agro		12.0	12.5	0.5	13.1	0.8	0.8	0.0	1.4
Pharma		4.8	5.2	0.4	4.7	2.1	2.6	0.5	2.2
Trading		21.2	22.5	1.3	22.1	0.7	0.7	0.0	0.6
Others		11.1	9.3	-1.8	9.2	0.1	0.0	-0.1	-0.1
Adjustment		-15.2	-15.3	-0.1	-16.6	-0.9	-0.9	0.0	-0.8
<b>Total</b>		<b>72.1</b>	<b>69.8</b>	<b>-2.3</b>	<b>70.0</b>	<b>8.3</b>	<b>6.6</b>	<b>-1.7</b>	<b>8.0</b>

(1)1H FY2010 and 1H FY2011 Outlook as of May 2011 are restated based on new segment

# 1H FY2011 Review by Segment (New segmentation)

## (Chemicals)

(vs.1H FY2010)

- ◆OP up ¥0.2billion, due to recovery of Fine Chemicals (especially Custom Chemicals)
- ◆Basic Chemicals' profit down due to naphtha cost increase as well as decrease in sales of melamine

(vs.1H FY2011 Outlook as of May 2011)

- ◆OP down ¥0.3billion due to sales decrease in melamine and fixed cost increase

## (Performance Materials)

(vs.1H FY2010)

- ◆Sales down ¥2.7billion, OP down ¥2.3billion
- ◆Sales decrease in TN, VA, non-BARC ArF, SNOWTEX, substantial sales increase in IPS / FFS
- ◆Fixed cost increase (new SNOWTEX plant, R&D expenses)

(vs.1H FY2011 Outlook as of May 2011)

- ◆Sales down ¥1.9billion, OP down ¥1.0billion
- ◆Sales decrease in SUNEVER, Inorganic Materials (BARC sales flat)

## (Agro)

(vs.1H FY2010)

- ◆No development milestone payment of animal health product received (¥0.5billion in 1H FY2010)
- ◆But, Sales up ¥0.5billion, OP flat
- ◆Inventory adjustment of ROUNDUP almost completed, sales of other products increase

(vs.1H FY2011 Outlook as of May 2011)

- ◆Sales down ¥0.6billion, OP down ¥0.6billion
- ◆Advanced purchase of ROUNDUP and other products by consumers in March 2011 after the Great East Japan Earthquake adversely affected sales in 1H
- ◆Insecticide sales below expectations due to natural conditions
- ◆Export above expectations

## (Pharmaceuticals)

(vs.1H FY2010)

- ◆Sales up ¥0.4billion (milestones up ¥0.3billion, LIVALO up ¥0.3billion, others down ¥0.2billion), cost reduction, OP up ¥0.5billion

(vs.1H FY2011 Outlook as of May 2011)

- ◆Sales up ¥0.5billion, OP up ¥0.4billion due to LIVALO's better performance in both domestic and export markets

## (Trading)

(vs.1H FY2010 and vs.1H FY2011 Outlook as of May 2011)

- ◆Sales and OP up due to better trading activities (OP vs.1H FY2010 flat)

# FY2011 Outlook

(¥billion)

	FY2010			FY2011E			Change		
	1H	2H	Total	1H	2H E	Total	1H	2H E	Total
Sales	72.1	82.1	154.2	69.8	86.2	156.0	-2.3	4.1	1.8
Operating Profit	8.3	11.5	19.8	6.6	11.9	18.5	-1.7	0.4	-1.3
Non-Operating Income/Expenses	-0.5	0.1	-0.4	-0.1	0.1	0.0	0.4	0.0	0.4
Ordinary Income	7.8	11.6	19.4	6.5	12.0	18.5	-1.3	0.4	-0.9
Extraordinary Profit/Loss (1)	-	-0.5	-0.5	-	0.2	0.2	-	0.7	0.7
Net Income	5.6	7.4	13.0	4.4	8.3	12.7	-1.2	0.9	-0.3
EBITDA (2)	13.2	17.0	30.2	11.5	17.7	29.2	-1.7	0.7	-1.0
EPS (¥)	32.81	43.13	75.94	25.88	48.78	74.66	-6.93	5.65	-1.28
Dividend (¥/share)	¥12	¥12	¥24	¥12	¥12	¥24	0.0	0.0	0.0
Total amount of Dividend	2.1	2.0	4.1	2.1	2.0	4.1	0.0	0.0	0.0
OP Margin (%)	11.6%	14.0%	12.9%	9.4%	13.7%	11.9%	-2.2%	-0.3%	-1.0%
FX Rate (¥/\$)	89	82		80	80				
Naphtha (¥/kl)	46,900	48,500		55,000	52,000				

FY2011 Outlook as of May 2011		
1H E	2H E	Total
70.0	86.0	156.0
8.0	12.3	20.3
0.2	0.2	0.4
8.2	12.5	20.7
-	0.7	0.7
5.5	9.3	14.8
13.0	18.0	31.0
32.33	54.67	87.00
¥12	¥12	¥24
2.1	2.0	4.1
11.4%	14.3%	13.0%
83	83	
59,000	59,000	

(1) 2H FY2010 : Reversal of provision for loss on business liquidation +0.1,  
One-time losses caused by a change in employees' retirement benefit plan -0.6  
2H FY2011E: Gain on transfer of business+0.7、Devaluation of investments in securities -0.5

(2) EBITDA = Operating Profit + Depreciation

# 2H FY2011 Outlook

<vs. 2H FY2010>

(Sales) ◆Up ¥4.1 billion(+5.0%) (+) Chemicals, Performance Materials, Trading  
(-) Agrochemicals, Pharmaceuticals

(OP) ◆Up ¥0.4 billion(+3.5%) (+) Chemicals, Performance Materials, Trading  
(-) Agrochemicals, Pharmaceuticals

(Ordinary Income) ◆Up ¥0.4 billion(+3.4%)

(Net Income) ◆Up ¥0.9 billion(+12.2%)

<vs. 2H FY2011 Outlook as of May 2011>

(Sales) ◆Up ¥0.2 billion (+) Chemicals, Agrochemicals, Trading  
(-) Performance Materials, Pharmaceuticals

(OP) ◆Down ¥0.4 billion (+) Chemicals, Agrochemicals, Pharmaceuticals  
(±) Trading  
(-) Performance Materials

(Non-Operating Income and Expenses) ◆Down ¥0.1 billion

(Ordinary Income) ◆Down ¥0.5 billion

(Extraordinary Profit and Loss) ◆Down ¥0.5 billion Devaluation of investments in securities -0.5

(Net Income) ◆Down ¥1.0 billion

<Dividend > ◆¥12 Same as 2H FY2011 Outlook as of May 2011

# FY2011 Cash Flow Outlook

(¥billion)

	FY2010	FY2011E	FY2011 Outlook as of May2011
<b>CF from operating activities</b>	<b>24.7</b>	<b>19.0</b>	<b>21.7</b>
Profit before income tax	18.9	18.7	21.4
Depreciation & Amortization	10.4	10.7	10.7
Tax	-6.5	-6.1	-6.7
Working capital, others	1.9	-4.3	-3.7
<b>CF from investing activities</b>	<b>-8.3</b>	<b>-12.6</b>	<b>-13.1</b>
Purchase of investments in securities	0.6	-0.9	0.0
Purchase of PPE	-8.5	-11.2	-13.1
Others	-0.4	-0.5	0.0
<b>CF from financing activities</b>	<b>-9.6</b>	<b>-6.0</b>	<b>-8.6</b>
Dividends paid	-4.5	-4.0	-4.0
Borrowings	-2.2	-1.9	-4.6
Purchase of treasury shares	-2.8	0.0	0.0
Others	-0.1	-0.1	0.0
Effect of FX rate changes on cash & cash equivalents	-0.5	-0.4	0.0
<b>Change in cash &amp; cash equivalents</b>	<b>6.3</b>	<b>0.0</b>	<b>0.0</b>
<b>Cash &amp; cash equivalents at end of period</b>	<b>21.1</b>	<b>21.1</b>	<b>21.1</b>

(Blank)



# FY2011 Sales Outlook by Segment<sup>(1)</sup>

(¥billion)

	FY2010			FY2011E			Change			FY2011 Outlook as of May 2011		
	1H	2H	Total	1H	2H E	Total	1H	2H E	Total	1H E	2H E	Total
Chem	18.5	19.6	38.1	18.6	20.7	39.3	0.1	1.1	1.2	18.6	19.7	38.3
Fine Chemicals	6.1	5.2	11.3	5.9	5.9	11.8	-0.2	0.7	0.5	5.9	5.9	11.8
Basic Chemicals	12.4	14.4	26.8	12.7	14.8	27.5	0.3	0.4	0.7	12.7	13.8	26.5
Performance Materials	19.7	18.3	38.0	17.0	20.3	37.3	-2.7	2.0	-0.7	18.9	21.4	40.3
Agro	12.0	22.4	34.4	12.5	22.2	34.7	0.5	-0.2	0.3	13.1	21.9	35.0
Pharma	4.8	4.8	9.6	5.2	4.6	9.8	0.4	-0.2	0.2	4.7	5.0	9.7
Trading	21.2	22.9	44.1	22.5	25.8	48.3	1.3	2.9	4.2	22.1	24.8	46.9
Others	11.1	15.9	27.0	9.3	11.1	20.4	-1.8	-4.8	-6.6	9.2	11.1	20.3
Adjustment	-15.2	-21.8	-37.0	-15.3	-18.5	-33.8	-0.1	3.3	3.2	-16.6	-17.9	-34.5
<b>Total</b>	<b>72.1</b>	<b>82.1</b>	<b>154.2</b>	<b>69.8</b>	<b>86.2</b>	<b>156.0</b>	<b>-2.3</b>	<b>4.1</b>	<b>1.8</b>	<b>70.0</b>	<b>86.0</b>	<b>156.0</b>

(1) 2H FY2010 Actual and 2H FY2011 Outlook as of May 2011 : pro forma sales by new segment

# FY2011 OP Outlook by Segment<sup>(1)</sup>

										(¥billion)			
		FY2010			FY2011E			Change			FY2011 Outlook as of May 2011		
		1H	2H	Total	1H	2HE	Total	1H	2HE	Total	1HE	2HE	Total
Chem		0.6	1.8	2.4	0.8	2.1	2.9	0.2	0.3	0.5	1.1	1.9	3.0
	Fine Chemicals	-	-	-	-	-	-	-	-	-	-	-	-
	Basic Chemicals	-	-	-	-	-	-	-	-	-	-	-	-
Performance Materials		4.9	3.0	7.9	2.6	4.3	6.9	-2.3	1.3	-1.0	3.6	5.2	8.8
Agro		0.8	4.0	4.8	0.8	3.4	4.2	0.0	-0.6	-0.6	1.4	3.0	4.4
Pharma		2.1	2.3	4.4	2.6	1.7	4.3	0.5	-0.6	-0.1	2.2	1.5	3.7
Trading		0.7	0.7	1.4	0.7	0.9	1.6	0.0	0.2	0.2	0.6	0.9	1.5
Others		0.1	0.9	1.0	0.0	0.3	0.3	-0.1	-0.6	-0.7	-0.1	0.3	0.2
Adjustment		-0.9	-1.2	-2.1	-0.9	-0.8	-1.7	0.0	0.4	0.4	-0.8	-0.5	-1.3
Total		8.3	11.5	19.8	6.6	11.9	18.5	-1.7	0.4	-1.3	8.0	12.3	20.3

(1) 2H FY2010 Actual and 2H FY2011 Outlook as of May 2011 : pro forma OP by new segment

# 2H FY2011 Outlook by Segment (New segmentation)

## (Chemicals)

(vs.2H FY2010)

- ◆ Sales up ¥1.1billion, OP up ¥0.3billion
- ◆ Price increase in major products
- ◆ Sales of major products up (except melamine), fixed cost reduction
- ◆ Negative impact by naphtha price increase and melamine sales decrease (major customers hit by the Earthquake)

(vs.2H FY2011 Outlook as of May 2011)

- ◆ Sales up ¥1.0billion, OP up ¥0.2billion
- ◆ Price increase in major products
- ◆ Domestic melamine sales down due to the Earthquake

## (Performance Materials)

(vs.2H FY2010)

- ◆ Sales up ¥2.0billion, OP up ¥1.3billion
- ◆ Sales increase in BARC, IPS / FFS, Inorganic Materials and new products
- ◆ Sales decrease in TN, VA, non-BARC ArF

(vs.2H FY2011 Outlook as of May 2011)

- ◆ Sales down ¥1.1billion, OP down ¥0.9billion
- ◆ Sales of major products below Outlook as of May 2011

## (Agro)

(vs.2H FY2010)

- ◆ Sales down ¥0.2billion, OP down ¥0.6billion
- ◆ Cost increase (raw materials, depreciation of new Biological Research Lab, R&D expenses)

(vs.2H FY2011 Outlook as of May 2011)

- ◆ Sales up ¥0.3billion, OP up ¥0.4billion
- ◆ Improvement in pricing, purchasing expenses, cost reduction
- ◆ Sales of ROUNDUP and in-house developed products up vs. Outlook as of May 2011

## (Pharmaceuticals)

(vs.2H FY2010)

- ◆ Sales down ¥0.2billion (milestones down ¥0.5billion, LIVALO up ¥0.2billion, others up ¥0.1billion)
- ◆ Cost increase caused by depreciation of new Biological Research Lab

(vs.2H FY2011 Outlook as of May 2011)

- ◆ Sales down ¥0.4billion, OP up ¥0.2billion
- ◆ Sales down caused by advanced purchase of LIVALO in overseas market in 1H
- ◆ Fixed cost reduction

## (Trading)

(vs.2H FY2010)

- ◆ Sales and OP increase due to increased trading activities

(vs.2H FY2011 Outlook as of May 2011)

- ◆ Almost flat

# Chemicals – ① Fine Chemicals subsegment

Product	Characteristics and Trend	Non-consolidated Sales YOY Change					
		FY2011 Outlook as of October 2011			FY2011 Outlook as of May 2011		
		1H Actual	2H E	FY 2011E	1H E	2H E	FY 2011E
<b>Total Subsegment</b>		-3%	+13%	+4%	-4%	+13%	+4%
<b>TEPIC</b>	<ul style="list-style-type: none"> <li>◆ Epoxy compound for : solder resist, LED sealant, powder coating hardening agent for paint (automobiles, electric appliances)</li> <li>◆ World largest producer</li> <li>◆ Demand for electronic materials declined in 1H, demand for painting material expected to increase in 2H</li> <li>◆ Price increase being implemented</li> </ul>	-12%	+4%	-4%	-3%	+1%	-1%
<b>Environmental related products</b>	<ul style="list-style-type: none"> <li>◆ HI-LITE : made from chlorinated isocyanuric acid, used for sterilizing, disinfectant for swimming pool as well as water purification tank</li> <li>◆ Sales down in 1H due to the Earthquake, sales of value-added products expected to increase in 2H</li> </ul>	-11%	+6%	-4%	-8%	+6%	-2%
<b>Custom Chemicals</b>	<ul style="list-style-type: none"> <li>◆ Custom manufacturing and process researching services for pharmaceutical ingredients and intermediaries from pre-clinical to commercial production stages</li> <li>◆ New plant completed in July 2010 (capex ¥ 2.0 billion)</li> <li>◆ New contracts increasing, depreciation costs of new plant down</li> </ul>	+29%	+23%	+27%	-11%	+68%	+23%

Three products account for 82% of total non-consolidated subsegment sales (FY2010)


# Chemicals – ② Basic Chemicals subsegment

Product	Characteristics and Trend	Non-consolidated Sales YOY Change					
		FY2011 Outlook as of October 2011			FY2011 Outlook as of May 2011		
		1H Actual	2H E	FY 2011E	1H E	2H E	FY 2011E
<b>Total Subsegment</b>		<b>+2%</b>	<b>+4%</b>	<b>+3%</b>	<b>+3%</b>	<b>-4%</b>	<b>-1%</b>
<b>Melamine</b>	<ul style="list-style-type: none"> <li>◆ Mainly used as adhesive agent for medium density fiberboard, particle board</li> <li>◆ Domestic demand down due to the Earthquake's damage on customers</li> <li>◆ Export volume up though pricing trend is weak</li> </ul>	<b>-12%</b>	<b>-13%</b>	<b>-13%</b>	<b>+3%</b>	<b>-16%</b>	<b>-7%</b>
<b>Urea including AdBlue</b>	<ul style="list-style-type: none"> <li>◆ Urea: mainly used for urea formaldehyde resin, adhesive agent</li> <li>◆ AdBlue: solution of urea in demineralised water for diesel trucks to reduce NOx</li> <li>◆ Sales of both products increasing, but AdBlue is below targets due to the Earthquake</li> <li>◆ Price increase being implemented</li> </ul>	<b>+16%</b>	<b>+52%</b>	<b>+35%</b>	<b>+16%</b>	<b>+21%</b>	<b>+19%</b>
<b>High purity sulfuric acid</b>	<ul style="list-style-type: none"> <li>◆ Used to clean semiconductors</li> <li>◆ Largest in domestic market</li> <li>◆ Capacity expansion completed in May 2011 to accommodate increasing demand (production capacity +15% )</li> <li>◆ Negative impact by the Earthquake in 1Q, but demand growing afterwards</li> <li>◆ Price increase of sulfuric acid products being implemented</li> </ul>	<b>-1%</b>	<b>+21%</b>	<b>+10%</b>	<b>+6%</b>	<b>+15%</b>	<b>+11%</b>

Four products account for 35% of total non-consolidated subsegment sales(FY2010)

# Chemicals – ③ Flow Chart of Selected Basic Chemicals Products

- ◆ **Core products: Ammonia related products and sulfuric acid related products**
- ◆ **FY2010 ammonia domestic market share 8%, large percentage of self-consumption of ammonia**



# Performance Materials – ① SUNEVER

## ◆ 1H FY2011 Actual ( vs. 1H FY2010 )

Sales down 23%

Substantial sales increase in IPS / FFS, but larger sales decrease in TN and VA

## ( vs. 1H FY2011 Outlook as of May 2011 )

Sales down vs. May Outlook

Demand for all types below expectations due to market conditions

## ◆ 2H FY2011 Outlook ( vs. 2H FY2010 )

Sales up 4%

Continued substantial sales increase in IPS / FFS

## ( vs. 2H FY2011 Outlook as of May 2011 )

Sales down vs. May Outlook

Demand for all types below expectations due to market conditions

	Major Use	Consolidated Sales YOY Change					
		FY2011 Outlook as of October 2011			FY2011 Outlook as of May 2011		
		1H Actual	2H E	FY 2010E	1H E	2H E	FY 2010E
<b>Total SUNEVER</b>		-23%	+4%	-10%	-5%	+21%	+7%
<b>TN</b> (twisted nematic)	PC, monitor	-31%	-16%	-25%	-19%	-6%	-14%
<b>IPS/FFS</b> (in plane switching / fringe field switching)	TV, tablet PC, smart phone	-13%	+26%	+6%	+14%	+51%	+32%
<b>VA</b> (vertical alignment)							

# Performance Materials – ② BARC

## ◆ 1H FY2011 Actual ( vs. 1H FY2010 )

Sales down 15%

Sales of both KrF and ArF (especially non-BARC ArF) down

## ( vs. 1H FY2011 Outlook as of May 2011 )

Sales flat vs. May Outlook

BARC ArF above expectations

## ◆ 2H FY2011 Outlook ( vs. 2H FY2010 )

Sales down 1%

Sales increase in BARC ArF, decrease in KrF and non-BARC ArF

## ( vs. 2H FY2011 Outlook as of May 2011 )

Sales down vs. May Outlook

BARC ArF above expectations, KrF and non-BARC ArF below expectations

	Line Width	Consolidated Sales YOY Change					
		FY2011 Outlook as of October 2011			FY2011 Outlook as of May 2011		
		1H Actual	2H E	FY 2011E	1H E	2H E	FY 2011E
<b>Total BARC</b>		-15%	-1%	-8%	-15%	+2%	-7%
<b>KrF</b>	130nm~ 110nm	-19%	-7%	-13%	-18%	-4%	-11%
<b>ArF</b> (including non-BARC ArF)	90nm>	-12%	+2%	-5%	-14%	+5%	-5%

## ◆ Solid progress being achieved in developing materials for EUV



# Performance Materials – ③ Inorganic Materials

## ④ New Products

### ◆ Inorganic Materials (SNOWTEX, Organo sol)

Product	Characteristics and Trend	Non-consolidated Sales YOY Change					
		FY2011 Outlook as of October 2011			FY2011 Outlook as of May 2011		
		1H Actual	2H E	FY 2011E	1H E	2H E	FY 2011E
<b>SNOWTEX</b>	<ul style="list-style-type: none"> <li>◆ Silica sol for : polishing silicon wafer/aluminum and glass hard disk, NOx reduction catalyst, automobile catalyst, chrome-free electrical steel sheet</li> <li>◆ Largest domestic producer, major global producer</li> <li>◆ New second plant in Toyama completed in March 2011 (production capacity +20% )</li> <li>◆ In 1H 2011, sluggish demand for polishing applications, in contrast with solid demand for non-polishing applications</li> <li>◆ In 2H 2011, recovery of demand for polishing applications expected</li> </ul>	-9%	+17%	+4%	-5%	+15%	+5%
<b>Organo sol</b>	<ul style="list-style-type: none"> <li>◆ Used for hard coating materials, electronic information materials</li> <li>◆ World largest producer</li> <li>◆ In 1H 2011, sluggish demand for electronic information materials</li> <li>◆ In 2H 2011, recovery of demand for electronic information materials and sales increase for new applications expected</li> </ul>	-5%	+42%	+16%	-5%	+23%	+7%

### ◆ New Products

Sales of new products such as NHC (protection layer of touch panel), multi layer process materials, 3DTV materials, microlens increasing substantially

(Blank)

# Agrochemicals – ①

## ◆ Stable profit center

## ◆ Strengthening product portfolio by: (a) in-house developed products, (b) acquired products, (c) licensed-in products

(a) In-house developed products : LEIMEY(fungicide), STARMITE(miticide) in FY2008

(b) Acquired products : ROUNDUP(herbicide, acquired from Monsanto) in FY2002,  
THIFLUZAMIDE(fungicide, acquired from Dow) in FY2009

(c) Licensed-in products : PREVATHON(insecticide, licensed from DuPont) in FY2009,  
AVH(herbicide, licensed from ZEN-NOH, Bayer and Hokko)  
in FY2010

## ◆ Pipeline

- NC620 (paddy rice herbicide, launch FY2013)
- Animal health product (licensing product, launch FY2014)
- Fruits/vegetables insecticide, paddy rice herbicide

## ◆ Full reconstruction of Biological Research Laboratories (FY2010-2015)

## ◆ Acquired 3% share of IHARABRÁS (leading agro company in Brazil) in September 2011 to strengthen R&D and marketing capabilities in the rapidly growing market in Latin America

## ◆ Export sales account for about 20% of total non-consolidated segment sales(FY2010) (Asia:42%, Europe,Africa:31%, North/Central/South America:26%)

## Agrochemicals – ② Non-consolidated Segment Sales (before discount)


	Non-consolidated Sales YOY Change <sub>(before discount)</sub>					
	FY2011 Outlook as of October 2011			FY2011 Outlook as of May 2011		
	1H Actual	2H E	FY 2011E	1H E	2H E	FY 2011E
<b>ROUNDUP</b>	+33%	+0%	+9%	+46%	-8%	+6%
<b>Except ROUNDUP</b>	-2%	+1%	+0%	+4%	+1%	+2%
<b>Total Segment</b>	+4%	+0%	+2%	+12%	-1%	+3%

	Distribution of NCI Non-consolidated Sales	
	FY2010	FY2011E
<b>Fungicide +Insecticide</b>	3%	3%
<b>Insecticide</b>	19%	17%
<b>Fungicide</b>	11%	12%
<b>Herbicide</b>	62%	65%
<b>Plant growth regulator</b>	2%	2%
<b>Others</b>	2%	1%

# Pharmaceuticals – ① NCI Business Model


- ◆ Steadily expanding segment in mid-term perspective
- ◆ Unique ethical pharma business model without sales force

< Before Launch > → < After Launch >



# Pharmaceuticals – ② LIVALO

- ◆ Domestic market share up steadily (Actual 1H FY2011 market share: 16%)
- ◆ Started USA sales in June 2010, co-distribution by Kowa and Eli Lilly
- ◆ Started EU sales in May 2011
- ◆ New plant completed in March 2011
- ◆ Full reconstruction of Biological Research Laboratories (FY2010-2015)



# Pharmaceuticals – ③ LIVALO World Wide Strategy

Country /Region	Stage of Development	Launch (schedule)	Business partner
Japan	Launched	Sep 2003	Kowa, Daiichi-Sankyo
Korea	Launched	Jul 2005	JW Pharmaceutical
Thailand	Launched	Jan 2008	Biopharm-Chemical
China	Launched	Jul 2009	Kowa Shanghai
USA	Launched	Jun 2010	Kowa(KPA), Eli Lilly
Europe	Launched	May 2011	Kowa(KPE), Recordati
Taiwan	Approved	2011	Taiwan Tanabe
Middle East/ North Africa	Applied	2011	Algorithm
Central and South America	Applied	2011	Eli Lilly
Indonesia	Applied	2012	Indonesia Tanabe
Australia / New Zealand	Applied	2012	Abbott

# Pharmaceuticals – ④ Pipeline

Product	Market		Developing Status	Licensee	Expected Market Size (¥ billion)
LIVALO (Anti-cholesterol agent)	USA		Launched	Kowa	2,500
	EU		Launched		
NM/NT-702 (Anti-platelet agent)	Japan	Intermittent claudication	Phase II	Taisho	20-30
		Asthma			20
	EU/USA	Intermittent claudication	Phase II completed	Indigo(USA)	50-70(USA)
NTC-801 (Anti-arrhythmic agent)	Japan		Phase II	Teijin	1 million patients(2015)
	World wide(except Japan)		Phase II	BMS	8.4 million patients(2015)
NIP-022 (Platelet generating stimulator agent)			Phase I	Ono	0.35million patients (2015 in Japan)



# Capex/Depreciation/R&D by Segment (¥billion)

(Former Segmentation)	Capex(1)	Depreciation(2)	R&D expenses
	2010	FY2010	FY2010
Chem	4.4	4.5	1.3
Electronic	1.2	3.0	5.1
Agro	0.4	1.9	2.6
Pharma	2.4	0.3	2.4
Trading	0.2	0.1	0.0
Others	1.0	0.6	1.2
<b>Total</b>	<b>9.6</b>	<b>10.4</b>	<b>12.6</b>

(New Segmentation)	Capex(1)					Depreciation(2)					R&D expenses					% of Sales
	2007	2008	2009	2010	2011E	2007	2008	2009	2010	2011E	2007	2008	2009	2010	2011E	
Chem	-	-	-	1.9	2.8	-	-	-	3.4	2.9	-	-	-	0.8	0.9	2.3%
Perf. Materials	-	-	-	3.7	2.4	-	-	-	4.1	4.2	-	-	-	5.6	6.2	16.4%
Agro	-	-	-	0.4	0.6	-	-	-	1.9	2.0	-	-	-	2.6	2.7	7.8%
Pharma	-	-	-	2.4	0.3	-	-	-	0.3	1.0	-	-	-	2.4	2.5	25.5%
Trading	-	-	-	0.2	0.0	-	-	-	0.1	0.1	-	-	-	0.0	0.0	0.0%
Others	-	-	-	1.0	3.3	-	-	-	0.6	0.5	-	-	-	1.2	1.4	7.0%
<b>Total</b>	<b>10.9</b>	<b>13.9</b>	<b>10.1</b>	<b>9.6</b>	<b>9.4</b>	<b>9.7</b>	<b>10.2</b>	<b>11.0</b>	<b>10.4</b>	<b>10.7</b>	<b>12.5</b>	<b>13.7</b>	<b>13.1</b>	<b>12.6</b>	<b>13.7</b>	
<b>R&amp;D expenses/Sales (%)</b>											<b>7.4%</b>	<b>8.6%</b>	<b>8.8%</b>	<b>8.2%</b>	<b>8.8%</b>	

## (1) Capex

Actual - Acceptance basis

Outlook - Production commencement basis

## (2) Depreciation Method

SUNEVER, BARC- 4 year declining balance method  
(62.5% of initial capex amount in the 1<sup>st</sup> year)

Other products - 8 year declining balance method  
(31.3% of initial capex amount in the 1<sup>st</sup> year)


Number of R&D Personnel (Sept.2011) - ①	420 ( Parent company)
Number of Professionals (Sept.2011) - ②	1,035 ( Parent company)
①/②	41%

# FY2011 Main Capex Items (Approval basis)

(¥billion)

2011E	
NC-620 (Agro)	2.8
Electronic Materials Labo (Instruments)	1.2
Biological Research Labo	0.6

# Long-term Financial Performance Trend



\* 2002 = From April 1, 2002 to March 31, 2003

# Long Term Financial Performance Trend

(¥ billion)

	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011E
Sales	151.9	155.9	161.4	169.1	174.4	169.2	160.2	149.0	154.2	156.0
Operating Profit	9.8	15.7	17.3	21.7	20.8	24.8	17.4	19.2	19.8	18.5
Net Income	4.0	8.7	11.3	13.7	14.0	15.5	10.1	12.8	13.0	12.7
EBITDA	20.7	26.1	26.9	31.6	30.5	34.5	27.6	30.1	30.2	29.1
OP Margin	6.5%	10.0%	10.7%	12.8%	12.0%	14.6%	10.9%	12.8%	12.9%	11.9%
ROE(%)	6.7%	13.4%	15.2%	16.1%	14.7%	15.6%	10.3%	12.6%	11.9%	11.0%
EPS(¥)	21.16	46.21	59.77	72.73	75.43	85.15	57.26	74.00	75.94	74.66
Dividend(¥/share)	9	11	11	15	20	20	22	24	24	24
Purchases of treasury shares	-	-	-	-	4.7	5.0	8.0	-	2.8	-
Net Assets	60.6	69.2	78.5	92.0	98.1	100.1	95.7	106.5	112.4	-
Liabilities with interest	68.5	57.4	44.6	41.5	32.4	34.4	45.5	42.1	39.9	-
D/E ratio (1)	108.2%	78.0%	53.7%	38.5%	23.2%	27.2%	37.1%	26.0%	16.9%	-
Equity ratio	35.4%	40.1%	46.4%	50.2%	55.3%	58.0%	55.5%	58.7%	60.7%	-
Capex	18.8	6.6	6.6	9.2	12.1	10.9	13.9	10.1	9.6	9.4
Depreciation	10.9	10.4	9.6	9.9	9.7	9.7	10.2	11.0	10.4	10.7
R&D Expenses	7.5	8.7	8.6	9.2	9.9	12.5	13.7	13.1	12.6	13.7
R&D Expenses/Sales(%)	4.9%	5.6%	5.3%	5.4%	5.7%	7.4%	8.6%	8.8%	8.2%	8.8%
Number of employees (parent company)	1,514	1,505	1,502	1,502	1,558	1,614	1,657	1,710	1,750	-

(1) D/E ratio = (Borrowings - Cash) / Shareholders' equity

# Pro Forma Sales and Operating Profit by New Segmentation

		2010 (1)		2011E		( ¥billion)
SALES	Chemicals	38.1	24.7%	39.3	25.2%	
	Performance Materials	38.0	24.6%	37.3	23.9%	
	Agrochemicals	34.4	22.3%	34.7	22.2%	
	Pharmaceuticals	9.6	6.2%	9.8	6.3%	
	Trading	44.1	28.6%	48.3	31.0%	
	Others	27.0	17.5%	20.4	13.1%	
	Adjustment	-37.0	-24.0%	-33.8	-21.7%	
	Total	154.2	100%	156.0	100%	

OP	Chemicals	2.4	12.1%	2.9	15.7%	
	Performance Materials	7.9	39.9%	6.9	37.3%	
	Agrochemicals	4.8	24.2%	4.2	22.7%	
	Pharmaceuticals	4.4	22.2%	4.3	23.2%	
	Trading	1.4	7.1%	1.6	8.6%	
	Others	1.0	5.1%	0.3	1.6%	
	Adjustment	-2.1	-10.6%	-1.7	-9.2%	
	合計	19.8	100%	18.5	100%	

OP Margin	Chemicals	6.3%	7.4%	
	Performance Materials	20.8%	18.5%	
	Agrochemicals	14.0%	12.1%	
	Pharmaceuticals	45.8%	43.9%	
	Trading	3.2%	3.3%	
	Others	3.7%	1.5%	
	合計	12.9%	11.9%	

(1)1H FY2010 Actual : restated based on new segment

2H FY2010 Actual : pro forma sales and OP by new segment

# Pro Forma Sales and Operating Profit by Former Segmentation


( ¥ billion)

		FY2005		FY2006		FY2007		FY2008		FY2009		FY2010	
SALES	Chemicals	50.2	29.7%	55.2	31.6%	60.7	35.9%	55.4	34.6%	46.1	30.9%	49.6	32.2%
	Electronic Materials	23.4	13.9%	22.8	13.1%	28.1	16.6%	23.2	14.5%	26.6	17.9%	26.2	17.0%
	Agrochemicals	35.8	21.1%	33.5	19.2%	33.2	19.6%	35.4	22.1%	33.8	22.7%	34.4	22.3%
	Pharmaceuticals	5.1	3.0%	6.5	3.7%	8.1	4.8%	9.2	5.7%	9.5	6.4%	9.6	6.2%
	Trading	35.7	21.1%	40.4	23.2%	47.0	27.8%	46.3	28.9%	41.3	27.7%	44.1	28.6%
	Others (1)	53.4	31.6%	53.4	30.6%	28.0	16.5%	28.4	17.7%	27.4	18.4%	27.0	17.5%
	Adjustment	-34.4	-20.3%	-37.4	-21.4%	-35.9	-21.2%	-37.7	-23.5%	-35.7	-24.0%	-36.7	-23.8%
	Total	169.2	100%	174.4	100%	169.2	100%	160.2	100%	149.0	100%	154.2	100%
OP	Chemicals	4.6	21.3%	5.4	25.8%	6.3	25.4%	3.6	20.7%	2.6	13.5%	4.1	20.7%
	Electronic Materials	11.1	51.3%	9.4	45.0%	10.3	41.5%	4.9	28.2%	7.3	38.0%	6.2	31.3%
	Agrochemicals	3.7	17.2%	3.5	16.7%	4.1	16.5%	5.0	28.7%	4.7	24.5%	4.8	24.2%
	Pharmaceuticals	1.2	5.6%	2.1	10.0%	3.9	15.7%	4.5	25.9%	4.6	24.0%	4.4	22.2%
	Trading	0.8	3.8%	1.0	4.6%	1.0	4.0%	1.1	6.3%	1.1	5.7%	1.4	7.1%
	Others	0.9	4.1%	1.1	5.4%	0.8	3.2%	0.7	4.0%	1.0	5.2%	1.0	5.1%
	Adjustment	-0.7	-3.3%	-1.6	-7.4%	-1.6	-6.3%	-2.4	-13.8%	-2.1	-10.9%	-2.1	-10.6%
	Total	21.7	100%	20.8	100%	24.8	100%	17.4	100%	19.2	100%	19.8	100%
OP Margin	Chemicals	9.2%		9.8%		10.3%		6.5%		5.6%		8.3%	
	Electronic Materials	47.4%		41.1%		36.8%		21.0%		27.4%		23.7%	
	Agrochemicals	10.4%		10.4%		12.3%		14.0%		13.9%		14.0%	
	Pharmaceuticals	24.0%		32.2%		48.0%		49.5%		48.4%		45.8%	
	Trading	2.3%		2.4%		2.2%		2.4%		2.7%		3.2%	
	Others	1.7%		2.1%		2.7%		2.5%		3.6%		3.7%	
	Total	12.8%		11.9%		14.6%		10.9%		12.8%		12.9%	


(1) Sales of Others decreased in FY2007 mainly due to spin-off of Nissan Agri (currently “Sun Agro”) (fertilizer company, actual FY2006 sales ¥27.7 billion)

# Pro Forma Sales by Former Segmentation (¥ billion)


Chem




Electronic Materials




Agro





Pharma



Trading




Others




# Pro Forma Operating Profit by Former Segmentation (¥ billion)


Chem




Electronic Materials




Agro





Pharma



Trading



Others





# FY2009- 10 Quarterly Sales by Segment (Former Segmentation)

(¥ billion)

	FY2009					FY2010				
	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total
<b>Chemicals</b>	11.3	10.8	12.0	12.0	46.1	12.7	11.8	12.4	12.7	49.6
Organic/Inorganic Materials	4.5	4.5	5.0	5.2	19.2	5.4	5.0	4.8	5.1	20.3
Basic Chemicals	6.8	6.3	7.0	6.8	26.9	7.3	6.8	7.6	7.6	29.3
<b>Electronic Materials</b>	6.4	6.8	6.8	6.6	26.6	7.3	6.4	6.3	6.2	26.2
<b>Agrochemicals</b>	8.0	3.7	3.7	18.4	33.8	6.9	5.1	4.4	18.0	34.4
<b>Pharmaceuticals</b>	2.2	2.8	2.9	1.6	9.5	2.5	2.3	2.1	2.7	9.6
<b>Trading</b>	10.3	9.8	10.4	10.8	41.3	10.7	10.5	11.8	11.1	44.1
<b>Others</b>	8.2	5.1	7.0	7.1	27.4	6.5	4.6	4.3	11.6	27.0
<b>Adjustment</b>	-11.1	-7.5	-9.1	-8.0	-35.7	-7.6	-7.6	-8.6	-12.9	-36.7
<b>Total</b>	35.3	31.5	33.7	48.5	149.0	39.0	33.1	32.7	49.4	154.2

# FY2009- 10 Quarterly OP by Segment (Former Segmentation)

(¥ billion)

	FY2009					FY2010				
	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total
Chemicals	1.2	-0.7	1.0	1.1	2.6	1.6	0.2	1.1	1.2	4.1
Electronic Materials	2.1	2.6	1.3	1.3	7.3	2.1	1.7	1.4	1.0	6.2
Agrochemicals	1.0	-0.7	-1.3	5.7	4.7	0.8	0.0	-1.3	5.3	4.8
Pharmaceuticals	1.2	1.5	1.5	0.4	4.6	1.2	0.9	1.0	1.3	4.4
Trading	0.2	0.3	0.3	0.3	1.1	0.4	0.3	0.4	0.3	1.4
Others	0.5	-0.1	0.2	0.4	1.0	0.1	0.0	-0.1	1.0	1.0
Adjustment	-0.9	-0.4	-0.6	-0.2	-2.1	-0.4	-0.6	-0.3	-0.8	-2.1
<b>Total</b>	<b>5.3</b>	<b>2.5</b>	<b>2.4</b>	<b>9.0</b>	<b>19.2</b>	<b>5.8</b>	<b>2.5</b>	<b>2.2</b>	<b>9.3</b>	<b>19.8</b>

# Main Products by Segment (New Segmentation)

Segment	Products	Main Applications
Chem	<b>◆ Fine Chemicals</b> TEPIC Melamine cyanurate Environmetal product Custom Chemicals	epoxy compound for LED sealants, solder resist, painting flame retardant HI-LITE (chlorinated isocyanuric acid for sterilizing) custom manufacturing and process services for pharmaceutical companies
	<b>◆ Basic Chemicals</b> Melamine AdBlue Ammonia, Sulfuric acid, Nitric acid Highpurity chemicals	adhesive agent for plywood solution of urea in demineralised water for diesel trucks to reduce NOx agents used for cleaning semiconductors
Performance Materials	<b>◆ Electronic Materials</b> SUNEVER BARC NHC Micro lens	LCD alignment coating bottom anti-reflective coating for semiconductors protective coating for touch panel microlens material for image sensor application
	<b>◆ Inorganic Materials</b> SNOWTEX  Organo silica sol Alumina sol SUNCOLLOID CELNAX	water dispersed colloidal silica sol for polishing silicon wafers, electrical steel sheets, NOx reduction catalyst, electronic printing materials film coating, antistatic interference shielding, electronic printing materials automotive catalyst, electronic printing materials high refractive sol for lens antistatic sol for film
Agro	<b>◆ Herbicides</b> TARGA PERMIT SIRIUS ROUNDUP <b>◆ Insecticides</b> STARMITE, SANMITE, MITOKOHNE <b>◆ Fungicide</b> LEIMAY, IKARUGA	soybean, rapeseed, sugarbeet corn, sugarcane, rice rice non-selective herbicide for orchard, noncrop land  fruits,tea, vegetables  potato, grape, turf
Pharma	LIVALO	Anti-cholesterol drug
Trading	Nissei Corporation	
Others	Transportation, Landscaping, Engineering, Fertilizer	

# Main Products by Segment (Former Segmentation)

Segment	Products	Main Applications
Chem	<b>◆ Organic Materials</b> TEPIC Custom Chemicals Melamine cyanurate	epoxy compound for LED sealants, solder resist, painting custom manufacturing and process services for pharmaceutical companies flame retardant
	<b>◆ Inorganic Materials</b> SNOWTEX  Organo silica sol Alumina sol SUNCOLLOID CELNAX	water dispersed colloidal silica sol for polishing silicon wafers, electrical steel sheets, NOx reduction catalyst, electronic printing materials film coating, antistatic interference shielding, electronic printing materials automotive catalyst, electronic printing materials high refractive sol for lens antistatic sol for film
	<b>◆ Basic Chemicals</b> Melamine AdBlue Environmetal product Ammonia, Sulfuric acid, Nitric acid Highpurity chemicals	adhesive agent for plywood solution of urea in demineralised water for diesel trucks to reduce NOx HI-LITE (chlorinated isocyanuric acid for sterilizing)  agents used for cleaning semiconductors
Electronic Materials	SUNEVER BARC NHC Micro lens	LCD alignment coating bottom anti-reflective coating for semiconductors protective coating for touch panel microlens material for image sensor application
Agro	<b>◆ Herbicides</b> TARGA PERMIT SIRIUS ROUNDUP	soybean, rapeseed, sugarbeet corn, sugarcane, rice rice non-selective herbicide for orchard, noncrop land
	<b>◆ Insecticides</b> STARMITE, SANMITE, MITOKOHNE <b>◆ Fungicide</b> LEIMAY, IKARUGA	fruits, tea, vegetables  potato, grape, turf
Pharma	LIVALO	Anti-cholesterol drug
Trading	Nissei Corporation	
Others	Transportation, Landscaping, Engineering, Fertilizer	

# Forward Looking Statements

**The forward looking statements in this material are based on information available at the time of preparation of the material. Although they reflect our current expectations, these statements are not guarantees of future performance, but include a number of risks and uncertainties. Actual results may largely differ from these statements due to various factors which may be beyond company control.**

**No information in this material is provided as an offer to buy or sell the shares of the company. We urge users of the material to make investment decision based upon own judgment.**